Draupadi Talreja
Hematology & Oncology · Northridge, CANPI 1326073743
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $286,843 of the $385,472 with a category attached, or 74.4%. Daiichi Sankyo Inc. accounts for 88.6% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $122,686 and has fallen 98.4% since, to $1,943 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 584 payments — averaging $660.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$342K
- AMAG Pharmaceuticals, Inc.$17K
- AstraZeneca$12K
- Bristol Myers Squibb$5K
- Ipsen Biopharmaceuticals, Inc$3K
- Pharmacosmos Therapeutics Inc.$2K
- plus $5K from 24 others
What the payments were for
- Consulting fees$20,5035%
- Speaking & faculty fees$286,84374%
- Travel & lodging$65,00817%
- Food & beverage$13,0863%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 467 | $341,572 |
| AMAG Pharmaceuticals, Inc. | 27 | $16,824 |
| AstraZeneca(2 entities) | 30 | $11,971 |
| Bristol Myers Squibb | 11 | $5,360 |
| Ipsen Biopharmaceuticals, Inc | 7 | $2,597 |
| Pharmacosmos Therapeutics Inc. | 3 | $2,478 |
| Eisai Inc. | 5 | $556 |
| Lilly USA, LLC | 4 | $468 |
| Gilead(2 entities) | 4 | $442 |
| Baxter Healthcare | 2 | $375 |
| Sanofi | 1 | $350 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $316 |
| Sanofi-aventis U.S. LLC | 1 | $300 |
| E.r. Squibb & Sons, L.L.C. | 2 | $205 |
| Stemline Therapeutics Inc. | 2 | $199 |
| GSK | 2 | $161 |
| Abbott | 1 | $145 |
| Karyopharm Therapeutics Inc. | 1 | $136 |
| ASD Specialty Healthcare, LLC | 1 | $132 |
| Merck | 1 | $125 |
| Beigene USA, Inc. | 1 | $125 |
| Incyte Corporation | 1 | $125 |
| Seagen Inc. | 1 | $121 |
| Blueprint Medicines Corporation | 1 | $121 |
| GE HealthCare | 1 | $103 |
| Cardinal Health 110 LLC | 1 | $100 |
| Genentech USA, Inc. | 1 | $25 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$385,472 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Northridge
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.